Suven Life Sciences on Tuesday said that it has been granted one product patent each from New Zealand and Norway corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2034 and 2027, respectively.
The granted claims of the patents include the class of selective 5HT6 compounds and are being developed as therapeutic agents for major depressive disorders and for the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer’s disease, attention deficient hyperactivity disorder, Huntington’s disease, Parkinson’s and schizophrenia, respectively. Shares of Suven Life jumped 4.6 per cent at ₹188.75 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.